Celgene To Pay $62M To End Antitrust Suit Over Cancer Drugs
Pharmaceutical company Celgene Corp. has agreed to fork over $62 million to resolve claims that it has suppressed competition for the brand-name cancer drugs Thalomid and Revlimid by preventing lower-priced generic...To view the full article, register now.
Already a subscriber? Click here to view full article